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INTRODUCTION
Although highly active antiretroviral therapy
(HAART) has dramatically reduced the incidence
of opportunistic illnesses and substantially extended
lifespan in patients with acquired immunodeficiency
syndrome (AIDS) (1, 2), complications of central
nervous system (CNS) infections remain a major
cause of morbidity and mortality. Cryptococcal men-
ingitis is one of the most frequent forms of menin-
goencephalitis among AIDS patients (3-5). More-
over, its high mortality rate has not improved (6)
even with high-dose amphotericin B (AMPH-B)
treatment (7). More recently, liposomal ampho-
tericin B (L-AMB) has emerged as a new fungi-
cide to combat cryptococci. We used this newly ap-
proved fungicide in a case of intractable cryptococ-
cal meningoencephalitis in which treatment with
AMPH-B and flucytosine (5-FC), and then with
voriconazole (VRCZ) and/or fluconazole (FLCZ),
failed to eradicate cryptococcal organisms from the
cerebrospinal fluid (CSF). Although the treatment
finally succeeded in clearing cryptococci from the
CSF, it simultaneously caused brain edema secon-
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dary to immune reconstitution syndrome (IRS) (8).
The objective of the present case study was to evalu-
ate the efficiency of L-AMB for treating intractable
cryptococcal meningoencephalitis. In addition, the
presence of IRS in response to L-AMB treatment
was examined.
CASE REPORT
Patient presentation and laboratory findings
A 34-year-old woman with a diagnosis of AIDS
and cryptococcal meningoencephalitis was trans-
ferred to the AIDS Medical Center, Osaka National
Hospital, Japan. On admission, physical examina-
tion revealed diplopia, severe neck rigidity, and a
body temperature persisting at over 38.5. Her
mental status was drowsy but oriented, and she com-
plained of severe headache. CD4+ and CD8+ T-cell
counts were 13 and 270/μl, respectively, with a vi-
ral load of 180103 copies/μl. Hepatic and renal
function data were within normal ranges, as were the
white blood cell count and the level of C-reactive
protein. The serum cryptococcal C antigen level was
elevated 65,536-fold, and the CSF pressure was re-
markably high at 53 cm H2O. The CSF glucose level
was slightly low (Fig. 1). Cryptococcal organisms
were confirmed in biopsy material from a cervical
lymph node, detected microscopically in the CSF by
Indian ink staining, and observed in CSF cultures.
Magnetic resonance imaging (MRI) of the head
revealed the diffuse vascular enhancement charac-
teristic of meningitis. Multiple small lesions, con-
sistent with a diagnosis of cryptococcal meningitis,
were demonstrated in T2-weighted images at bilat-
eral basal nuclei. However, MRI showed no partial
inflammatory lesions.
Clinical course
Sets of AMPH-B (30 mg/day, 0.7 mg/kg43
kg) and 5-FC (1000 mg, q6h), and sets of VRCZ
(320 mg/day) and/or FLCZ (400 mg/day) were
used alternately for 2.5 months (Fig. 1). The first
trials of AMPH-B and 5-FC were interrupted due
to acute thrombocytopenia after the initial week. The
high CSF pressure and headache did not improve
even upon administration of VRCZ and FLCZ, whose
concentrations in the CSF were 2.0 and 27.7 μg/ml,
respectively. The CSF pressure decreased from 53
to 20 cm H2O by retrial of AMPH-B and 5-FC at
slightly lower doses ; however, cryptococcal organ-
isms continued to persist in the CSF. With improve-
ment of clinical presentations, namely headache and
diplopia, the patient was treated with HAART, con-
sisting of tenofovir (TDF ; 300 mg, qd), emtricit-
abine (FTC ; 200 mg, qd), and efavirenz (EFV ; 600
mg, qd). The antifungal drug was changed to FLCZ
(400 mg, qd) for maintenance therapy. Two months
from the initiation of this therapy, the patient was
discharged due to improving clinical presentations,
although cryptococcal organisms still remained in
the CSF.
After seven months of antiretroviral therapy, the
patient reported worsening noise in her ears and
Fig. 1. Medication regimen and laboratory data during the clinical course. Prednisolone treatment included pulse therapy with
methylprednisolone (500 mg/day) for the first three days.
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frequent headache, and MRI revealed partial inflam-
matory lesions (Fig. 2a). IRS with immune restora-
tion was not suspected at the site of the lesions be-
cause of a rising CD4 cell count of 103/μl. The pa-
tient was readmitted to the hospital a second time
for treatment, with cryptococci present in the CSF.
She received 5-FC (1,000 mg, q8h) and the newly
approved L-AMB (150 mg/day). Treatment was
continued for 12 days, but was then stopped due to
severe nausea and headache. MRI suggested stem
herniation due to a large area of inflammatory hy-
perintensity on T2-weighted images (Fig. 2b) and
deformation of the fourth cerebral ventricle. Imme-
diate steroid pulse therapy was conducted to sup-
press inflammation and glycerol was used to reduce
the cerebral pressure, since brain edema secondary
to immune reconstitution syndrome (IRS) had rap-
idly advanced. Steroid pulse therapy drastically re-
duced the edema. Subsequently, cryptococcal or-
ganisms were undetectable in the CSF in four tests,
even at 15 months. However, inflammation with
brain edema appeared again when the steroid dose
was lowered to less than 20 mg.
DISCUSSION
We report a case of intractable cryptococcal men-
ingoencephalitis in which administration of L-AMB
eradicated the cryptococcal infection. Simultane-
ously, treatment with L-AMB caused brain edema
secondary to IRS. This clinical presentation clearly
coincides with the four conditions of IRS : HAART,
clinical evidence of an inflammatory process incon-
sistent with the usual course of cryptococcosis, a ris-
ing CD4 cell count, and falling HIV-1 RNA levels
(8). In IRS, a memory mechanism of the pathogen
in opportunistic diseases is thought to contribute
to symptom deterioration in the process of immune
restoration (8-14). IRS associated with cryptococ-
cus frequently emerges in the early stages of treat-
ment after introducing HAART. However, IRS some-
times recurs after six months or more (9, 14). The
present case is valuable when considering a mecha-
nism of IRS because the association between the
timing of deterioration and its cause can be clearly
explained. It is a big clue that steroid therapy was
effective to the brain edema of this case. The re-
lated reaction indicates that a new immune reac-
tion occurred after treatment with L-ABM and the
steroid suppressed it. The synthesized mechanism,
including delayed IRS, will be discussed below.
There were key differences between the initial
and secondary treatments in relation to improve-
ments in the patient’s immune function and liposo-
malization of AMPH-B. During the first treatment,
macrophages that eradicate fungal invasion (15, 16),
may be inactivated by HIV (17). This inactivation
of the macrophages can reduce the efficacy of an
azole drug in suppressing meningoencephalitis since
the mode of action for azoles is fungistatic rather
than fungicidal. Indeed, the two azole drugs used
were ineffective in spite of sufficient penetration
into the CSF. During the second treatment, it is
believed that macrophages were activated because
HAART suppressed HIV. Moreover, L-AMB treat-
ment has several advantages over conventional an-
tifungal drugs. L-AMB has the potential to cross the
blood-brain barrier (18, 19), whereas AMPH-B
does not. Furthermore, liposomalization markedly
decreases the cytotoxicity of AMPH-B, making
high-dose administration possible. When vascular
permeability is exacerbated by infection, L-AMB
concentrates locally around infectious lesions, at a
level more than 15 times higher than AMPH-B (20-
22). Indeed, the secondary treatment eradicated
the cryptococcal infection fungicidally. However,
the activation of macrophages would likely have
been unstable even if the new immune response
eradicated cryptococcus organisms. The following
brain edema needed to be suppressed by steroid
therapy in our patient. Steroids suppress the im-
mune response and therefore can be effective in pre-
venting IRS (12, 23).
L-AMB was successful in eradicating intracta-
ble cryptococcal infections, but treatment with L-
AMB simultaneously caused IRS. However, L-AMB
should be used with caution, with differences in
a b
Fig. 2. T2-weighted MRI images. The condition of the two im-
ages has been unified in terms of the window width. (a) Before
the second treatment, a spotty inflammatory hyperintensity on
T2-weighted images appeared in the occipital area. (b) After
treatment, an inflammatory hyperintensity indicated a large
area of brain edema.
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immune status taken into consideration in order to
prevent IRS.
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